Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 symbols : Srne save search
Sorrento Therapeutics Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
Published: 2022-09-26 (Crawled : 14:00) - biospace.com/
SRNE | $0.02 -8.85% 200K
|
Health Technology
|
| O: -0.65%
H: 5.19%
C: -1.95%
treatment osteoarthritis trial therapeutics phase 2
Scilex, a Sorrento Company, Announces Initiation of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 in Subjects with Acute Low Back Pain
Published: 2022-05-18 (Crawled : 14:00) - globenewswire.com
SRNE | $0.02 -8.85% 200K
|
Health Technology
|
| O: -1.91%
H: 4.87%
C: -1.95%
sp-103 back phase 2
Sorrento Announces FDA Authorization to Proceed With Phase 2 Study of Abivertinib (Fujovee™) to Treat Metastatic Castrate Resistant Prostate Cancer (MAVERICK Trial)
Published: 2022-05-17 (Crawled : 17:00) - biospace.com/
SRNE | $0.02 -8.85% 200K
|
Health Technology
|
| O: 4.17%
H: 6.0%
C: 4.67%
fda authorization cancer phase 2 prostate cancer
Sorrento Reports FDA Clearance for the Commencement of a Phase 2/3 Study for Abivertinib in Treatment of Hospitalized Patients With Severe Pneumonia Due to COVID-19
Published: 2022-03-31 (Crawled : 14:00) - biospace.com/
SRNE | $0.02 -8.85% 200K
|
Health Technology
|
| O: 1.27%
H: 0.26%
C: -2.92%
covid-19 treatment fda clearance phase 2
Sorrento Announces Completion of Enrollment in US Phase 2 Clinical Trial for COVI-DROPS and Achievement of Interim Analysis Threshold in the UK
Published: 2022-01-19 (Crawled : 17:00) - biospace.com/
SRNE | $0.02 -8.85% 200K
|
Health Technology
|
| O: -2.06%
H: 0.0%
C: 0.0%
phase 2 trial drop enroll
Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Clinical Trial of COVI-MSC in COVID-19 Patients With Persistent Pulmonary Compromise After Recovery (Long-Hauler)
Published: 2022-01-18 (Crawled : 15:00) - biospace.com/
SRNE | $0.02 -8.85% 200K
|
Health Technology
|
| O: 2.35%
H: 0.0%
C: 0.0%
covid-19 health phase 2 trial covid brazil
Sorrento Begins Enrollment in Phase 2 Trial of Resiniferatoxin (RTX) for the Treatment of Pain Due to Knee Osteoarthritis (OA)
Published: 2021-12-07 (Crawled : 19:00) - globenewswire.com
SRNE | $0.02 -8.85% 200K
|
Health Technology
|
| O: -1.68%
H: 9.4%
C: 7.52%
treatment phase 2 xin osteoarthritis trial enroll
UPDATE – Sorrento Announces Encouraging Results From Two Phase 2 Studies of Abivertinib For Treatment Of Hospitalized Severe COVID-19 Patients
Published: 2021-10-27 (Crawled : 20:00) - globenewswire.com
SRNE | $0.02 -8.85% 200K
|
Health Technology
|
| O: 0.3%
H: 5.22%
C: 5.07%
covid treatment phase 2 results
Sorrento Announces Encouraging Results From Two Phase 2 Studies of Abivertinib For Treatment Of Hospitalized Severe COVID-19 Patients
Published: 2021-10-27 (Crawled : 19:00) - globenewswire.com
SRNE | $0.02 -8.85% 200K
|
Health Technology
|
| O: 0.3%
H: 5.22%
C: 5.07%
covid treatment phase 2 results
FDA Authorizes Sorrento Phase 2 Trial of Epidural Resiniferatoxin for the Orphan Indication of Control of Intractable Cancer Pain
Published: 2021-10-13 (Crawled : 13:15) - globenewswire.com
SRNE | $0.02 -8.85% 200K
|
Health Technology
|
| O: 2.45%
H: 0.52%
C: -0.15%
fda phase 2 cancer trial authorized
Sorrento Announces Enrollment of First Subject in Brazil Phase 2 Study of COVI-MSC for Treatment of COVID-19 Associated Acute Respiratory Distress in ICU Patients
Published: 2021-09-02 (Crawled : 16:00) - globenewswire.com
SRNE | $0.02 -8.85% 200K
|
Health Technology
|
| O: 0.22%
H: 1.42%
C: -0.11%
covid treatment phase 2 brazil respiratory enroll
Sorrento Announces Dosing of COVID-19 Patients in Phase 2 Clinical Trial for COVIDROPS, a Highly Potent Neutralizing Antibody Against SARS-CoV-2 Including Delta and Alpha Variants of Concern
Published: 2021-07-21 (Crawled : 14:00) - biospace.com/
SRNE | $0.02 -8.85% 200K
|
Health Technology
|
| O: 1.08%
H: 8.91%
C: 7.24%
covid phase 2 drop antibody trial sars-cov-2
Sorrento Announces Dosing of COVID-19 Patients in Phase 2 Clinical Trial for COVIDROPS, a Highly Potent Neutralizing Antibody Against SARS-CoV-2 Including Delta and Alpha Variants of Concern, in an At-Home Outpatient Setting in United Kingdom
Published: 2021-07-21 (Crawled : 14:00) - globenewswire.com
SRNE | $0.02 -8.85% 200K
|
Health Technology
|
| O: 1.08%
H: 8.91%
C: 7.24%
covid phase 2 drop antibody trial sars-cov-2
FDA Clears Sorrento Phase 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin (RTX) For Treatment of the Knee Pain in Osteoarthritis (OA) Patients
Published: 2021-07-06 (Crawled : 19:00) - globenewswire.com
SRNE | $0.02 -8.85% 200K
|
Health Technology
|
| O: -1.05%
H: 1.06%
C: -12.02%
treatment fda phase 2 opioid osteoarthritis trial fda clearance
Sorrento Announces Phase 2 Abivertinib Clinical Studies Have Completed Patient Enrollment in USA and Brazil with Top-Line Clinical Data Expected End of 3Q21
Published: 2021-06-22 (Crawled : 14:00) - biospace.com/
SRNE | $0.02 -8.85% 200K
|
Health Technology
|
| O: -0.92%
H: 4.99%
C: 3.72%
phase 2 brazil topline enroll
Sorrento Receives Authorization From the UK Regulatory Agency to Conduct a Phase 2 Clinical Trial for COVI-DROPS in an Outpatient Setting
Published: 2021-06-11 (Crawled : 21:00) - globenewswire.com
SRNE | $0.02 -8.85% 200K
|
Health Technology
| Email alert
Add to watchlist
phase 2 drop trial authorized
Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Pivotal Clinical Trial of COVI-MSC™ in Hospitalized COVID-19 Patients With Acute Respiratory Distress Syndrome
Published: 2021-05-20 (Crawled : 13:15) - globenewswire.com
SRNE | $0.02 -8.85% 200K
|
Health Technology
|
| O: 1.43%
H: 4.24%
C: 1.98%
covid phase 2 brazil respiratory trial authorized syndros
Sorrento Receives FDA Clearance to Proceed With Phase 2 Study for Sti-3031, an Anti-Pd-L1 Antibody, for Advanced Urothelial Carcinoma
Published: 2021-04-27 (Crawled : 16:00) - globenewswire.com
SRNE | $0.02 -8.85% 200K
|
Health Technology
|
| O: -1.43%
H: 9.54%
C: 6.4%
fda clearance fda phase 2 antibody clearance urothelial carcinoma
Sorrento Receives US FDA Clearance to Proceed With Phase 1 Study for STI-2099 (Intranasal COVIDROPS) in Healthy Volunteers and Outpatient Treatment for Newly Diagnosed COVID-19 Positive Patients
Published: 2021-03-02 (Crawled : 21:04) - globenewswire.com
SRNE | $0.02 -8.85% 200K
|
Health Technology
|
| O: 1.37%
H: 2.41%
C: -5.21%
covid fda clearance treatment fda phase 1 drop positive phase 3 phase 2 clearance
Sorrento Receives US FDA Clearance to Proceed With Phase 1 Clinical Trials for STI-2020 (COVI-AMG) in Healthy Volunteers and in Newly Diagnosed COVID-19 Patients
Published: 2020-12-09 (Crawled : 14:05) - globenewswire.com
SRNE | $0.02 -8.85% 200K
|
Health Technology
|
| O: 10.51%
H: 2.29%
C: -5.96%
covid fda clearance fda trial phase 3 phase 1 phase 2 clearance
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.